Hip Replacements
Study data from University of the Pacific update understanding of hip replacements
Published in Medical Letter on the CDC and FDA, October 4th, 2009
According to a study from the United States, "Rivaroxaban is a highly potent direct factor Xa inhibitor with competitive and reversible activity that is pending FDA approval for the indication of venous thromboembolism (VTE) prophylaxis in patients undergoing total knee replacement (TKR) or total hip replacement (THR) surgery. Unlike the currently prescribed VTE prophylactic agents, which require subcutaneous (SC) administration or exhibit an undesirable drug interaction/monitoring profile, this agent offers the convenience of once-daily oral dosing, without the inconvenience of laboratory monitoring."
"In multiple phase 3 trials, rivaroxaban has demonstrated superior...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Asthma
New asthma research reported from McMaster University - Oncology
Study results from Hogan & Hartson, LLP broaden understanding of oncology - Protalix Biotherapeutics, Inc.
Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease - Regulatory Actions
Research from J.A. Zivin and co-authors reveals new findings on regulatory actions - Tissue Engineering
Scientific Journal Gene Therapy Reports That Cardium's Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration - Clinical Trial Research
Scientists at Intermountain Medical Center, Cardiovascular Department publish research in clinical trial research - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
